NASDAQ
20.12.24
21:56 Uhr
0,570 US-Dollar
+0,022
+4,01 %
+4,01 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 06.12. | Athira Pharma, Inc.: Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND | 119 | GlobeNewswire (Europe) | BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| ATHIRA PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.11. | Athira exploring strategic alternatives after Alzheimer's failure | 1 | BioPharma Dive | ||
| 08.11. | Athira Pharma GAAP EPS of -$0.75 misses by $0.04 | 1 | Seeking Alpha | ||
| 07.11. | Athira Pharma, Inc.: Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates | 70 | GlobeNewswire (Europe) | BOTHELL, Wash., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and... ► Artikel lesen | |
| 07.11. | Athira Pharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.11. | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | 801 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen | |
| 18.10. | Athira Pharma faces Nasdaq delisting over share price | 1 | Investing.com | ||
| 18.10. | Athira Pharma, Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 26.09. | Athira Pharma stock plunges to 52-week low of $0.41 | 1 | Investing.com | ||
| 26.09. | Athira Pharma-Aktie stürzt auf 52-Wochen-Tief von 0,41 US-Dollar | 1 | Investing.com Deutsch | ||
| 20.09. | After Alzheimer's stumble, Athira lays off 70% of workforce and pivots to ALS small molecule | 2 | FierceBiotech | ||
| 19.09. | Athira Pharma stock faces pivot and workforce cuts amid trial setback - Mizuho | 1 | Investing.com | ||
| 18.09. | Athira Pharma-Aktie erreicht 52-Wochen-Tief bei 0,46 US-Dollar | 7 | Investing.com Deutsch | ||
| 17.09. | Athira Pharma, Inc.: Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases | 1 | GlobeNewswire (USA) | ||
| 17.09. | Athira Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Athira Pharma stock plunges to 52-week low of $0.46 | 1 | Investing.com | ||
| 06.09. | Athira Pharma CEO sells over $2.8k in company stock | 1 | Investing.com | ||
| 06.09. | Athira Pharma general counsel acquires shares, sells for $1.4k | 1 | Investing.com | ||
| 06.09. | Athira Pharma executive sells shares on clinical trial milestone | 1 | Investing.com | ||
| 06.09. | Athira Pharma executive sells shares worth $1,429 | 1 | Investing.com |
Seite:
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| INFLARX | 2,088 | -3,06 % | InflaRx startet Phase-2a-Studie mit INF904 in den USA | InflaRx hat in den USA den ersten Patienten in eine Phase-2a-Studie mit dem oralen C5aR-Inhibitor INF904 aufgenommen. Die Studie untersucht das Medikament bei chronischer spontaner Urtikaria (CSU) und... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| COHERUS | 1,484 | +2,77 % | Coherus BioSciences, Inc.: Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025 | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,220 | +0,91 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | BEDFORD, Mass., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular"), a biopharmaceutical company committed to improving vision in the real world through the development... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| CHIMERIX | 2,905 | +1,04 % | Chimerix, Inc.: Chimerix to Submit Dordaviprone for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma Before Year-End | Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,035 | -0,58 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY, in a Phase 1 Study in Patients with Solid Tumors | SOUTH SAN FRANCISCO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| SPERO THERAPEUTICS | 0,927 | +0,98 % | What 4 Analyst Ratings Have To Say About Spero Therapeutics | ||
| CIDARA THERAPEUTICS | 20,600 | -6,36 % | Cidara Therapeutics stock soars to 52-week high of $24.4 | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report |
ATHIRA PHARMA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,570 Euro und damit +4,01 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ATHIRA PHARMA INC finden Sie auf Wallstreet Online.
